1
Clinical Trials associated with rHSC-DIPGVax(Dana-Farber Cancer Institute)A Phase I Clinical Trial of Neo-antigen Heat Shock Protein Vaccine (rHSC-DIPGVax) in Combination With Checkpoint Blockade for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma in Childhood
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
100 Clinical Results associated with rHSC-DIPGVax(Dana-Farber Cancer Institute)
100 Translational Medicine associated with rHSC-DIPGVax(Dana-Farber Cancer Institute)
100 Patents (Medical) associated with rHSC-DIPGVax(Dana-Farber Cancer Institute)
100 Deals associated with rHSC-DIPGVax(Dana-Farber Cancer Institute)